14 filings
8-K
APLT
Applied Therapeutics Inc
13 Nov 19
Applied Therapeutics Reports Third Quarter 2019 Financial Results
7:15am
8-K
APLT
Applied Therapeutics Inc
12 Nov 19
Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock
9:24am
8-K
APLT
Applied Therapeutics Inc
4 Sep 19
Departure of Directors or Certain Officers
5:06pm
8-K
APLT
Applied Therapeutics Inc
4 Sep 19
Other Events
8:00am
8-K
APLT
Applied Therapeutics Inc
12 Aug 19
Applied Therapeutics Reports Second Quarter 2019 Financial Results
7:16am
8-K
l0mvne5qk68s
8 Aug 19
Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study
7:00am
8-K
77un6 nnj
6 Aug 19
Regulation FD Disclosure
8:10am
8-K
whfckn ru6w5kg1e1ai
24 Jun 19
Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 In Galactosemia
7:09am
8-K
ritbj3i3ereqtjfrab
21 Jun 19
Applied Therapeutics Reports First Quarter 2019 Financial Results
7:34am
8-K
7j4l49uxoapw5s48 pq7
7 Jun 19
AT-001, a novel, potent and selective aldose reductase inhibitor, is expected to start a pivotal study later this year
7:59am
8-K
jw29e
6 Jun 19
Departure of Directors or Certain Officers
4:05pm
8-K
ncw 1pkcp4qm97y66yc
28 May 19
Applied Therapeutics Announces Fda Orphan Drug Designation for AT-007 In Galactosemia
5:14pm
8-K
vvwkrsfq70 jmtgc
24 May 19
Other Events
4:24pm
8-K
bvf3pg9ao4y686n xl
16 May 19
Amendments to Articles of Incorporation or Bylaws
5:22pm
- Prev
- 1
- Next